The findings of a preclinical study, published in the journal Science Translational Medicine, Kither Biotech’s experimental drug– KIT2014 –has been found effective in treating cystic fibrosis (CF) and other lung diseases, reducing inflammation, relaxing the airways, and improving the functionality of CFTR modulators. The company said that Kither scientists discovered that a protein called PI3K gamma is a critical regulator of cAMP in structural and inflammatory cells in the lungs, and that KIT2014 replicates this function. The team added that treatment with KIT2014 induced airway relaxation and reduced inflammation in mouse models and expressed hopes that this treatment would prove beneficial to patients with lung disorders.